Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

301 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-01

Study Completion Date

2026-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is

• Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.

NCT00769574

Coronary Syndrome

COMPLETED NA

A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome

NCT06955143

Acute Coronary Syndrome Chronic Coronary Syndrome

RECRUITING

Multi-Markers In the Diagnosis of Acute Coronary Syndrome

NCT01134913

Acute Coronary Syndrome

COMPLETED

Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease

NCT05015270

Coronary Artery Disease

COMPLETED

Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases

NCT02179047

Stable Angina

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Rupture Acute Coronary Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acute coronary syndrome casued by plaque erosion(PE-ACS)

acute coronary syndrome patients casued by plaque erosion as identified by invasive optical coherence tomography in catheter labs.(PE-ACS)

Blood is drawn to test for specific biomarkers

Intervention Type DIAGNOSTIC_TEST

After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

acute coronary syndrome casued by plaque rupture(PR-ACS)

acute coronary syndrome patients casued by plaque rupture as identified by invasive optical coherence tomography in catheter labs.(PR-ACS)

Blood is drawn to test for specific biomarkers

Intervention Type DIAGNOSTIC_TEST

After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood is drawn to test for specific biomarkers

After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

people presenting with an acute coronary syndrome (ACS)-either non-ST-segment elevation myocardial infarction (NSTE-ACS); or ST-segment elevation myocardial infarction (STE-ACS), and subsequently underwent emergent coronary angiography followed by percutaneous coronary intervention (PCI). Culprit leisions were tested using optical coheren tomograpgy and pathological diagnosis(PE OR PR) were validated by 2 independent experienced core lab members.

Exclusion Criteria

* patients younger than 18 years or older than 85 years
* patients in cardiogenic shock
* prior coronary artery bypass grafting,
* patients with corornary stent thrombosis
* patients with left main coronary disease
* patients with congestive heart failure
* patients with life-threatening arrhythmia
* patients with thrombocytopenia patients with significant hepatic or renal impairment
* patients with septicemia, leukopenia, active inflammatory or malignant disease
* other factors compromising high-quality optical coherence tomography (OCT) imaging (e.g., severe vessel tortuosity or calcification, persistent no-reflow, lesions in distal segments, or an indeterminate culprit lesion)
* Individuals unable to provide informed consent were also excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No